Chinese pharmaceutical company BeiGene Korea's first new drug, 'Brukinsa', has been approved to be prescribed in general hospitals.

According to sources from related industry, the BTK inhibitor Brukinsa (Zanubrutinib) has passed the Drug Committee of tertiary hospitals such as Samsung Medical Center, SNUH, and Asan Medical Center.

As reimbursement is expected to be applied in May, it is believed that prescriptions will be available quite soon after being listed.

Brukinsa has been approved in Korea in 2022, as ▲ monotherapy for adults with mantle cell lymphoma (MCL) who have received at least one prior therapy, and ▲ monotherapy for adults with Waldenström's macroglo